Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @rpavaneijk
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @rpavaneijk
-
Ruben van Eijk proslijedio/la je Tweet
Come and join us in Brisbane
@AIBNatUQ. Level up on your mad science skills, and meet new friends while searching for a cure for#MND#ALS. Fully funded#PhD#scholarship available
- contact me s.ngo@uq.edu.au #PhdChat#phdlife#AcademicTwitter#AcademicChatterhttps://twitter.com/Ngo_Lab/status/1215509195866271744 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
What a great end of an excellent meeting by receiving the MND Clinical Poster prize for optimizing the use of the ALSFRS-R! The time may have come to say goodbye to the total score and make better use of its domain information in clinical trials.
#alsmndsymp#ALSSymppic.twitter.com/M4OilslvXO
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Ruben van Eijk proslijedio/la je Tweet
Funding from
@FightMND is going towards two studies in 2020 - a biomarker study and a clinical trial.#collaborationiskey@UQ_News#RBWH@UMCUtrecht@kingsmnd@NgoShyuan@Fred_Steyn#RobHenderson@LeonardvandBerg@rpavaneijk@AmmarAlChalabihttps://twitter.com/FightMND/status/1202813763801337856 …
1:15Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Last day already of an enlightening MNDA Symposium, excellent talk by
@Fred_Steyn about the importance of hypermetabolism and appetite loss in patients with ALS. Superb graphs.pic.twitter.com/WjBvwdNavN
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Ruben van Eijk proslijedio/la je Tweet
What a great idea.
@mndassoc would like people to donate their#walk2dfeet T-shirts to make a quilt. This will be raffled to support the#als fellows program. Hand shirts into rego desk if keen to contribute#ALSSymp#fundraising

pic.twitter.com/WgfmuNRGQJ
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Tofersen as promising therapeutic option for ALS. Results from phase 1 show treatment is safe and tolerable. Responder/non-responder analysis should be interpreted with caution. Interesting decline in neurofilament and late stage clinical trial is indicated
#alsmndsymppic.twitter.com/dtsNYJuJfJ
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Many interesting talks about innovations in clinical trial design evaluating multiple treatments simultaneously, PET-based pharmacodynamic markers and promising therapeutic strategies using stem cells and antisense oligonucleotides
#alsmndsymppic.twitter.com/CdUShyJG6w
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Excellent overview of biomarkers for MND by prof. Turner. Biomarkers can be very useful for multiple aspects of clinical trials, important to distinguish between the different aims: diagnostic, prognostic, predictive, pharmacodynamic and/or surrogate purposes
#alsmndsymppic.twitter.com/MnzDkUgL6u
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Most original start of the MNDA Symposium so far, looking forward to a great meeting!
#alsmndsymppic.twitter.com/awIfdl4Up3
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Ruben van Eijk proslijedio/la je Tweet
Hopes of minimising burden for patients as much as possible
@profcjmcdermott@rpavaneijk collaborative road map#encals to best harness technology to improve the delivery of care & clinical trials for people with MND/ALS. How to best integrate and implement#alsmndsymp#alssymppic.twitter.com/BdN66hpYle
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Interesting discussion at
#encals about plateaus in ALSFRS-r decline, they are common and may occur already early in the disease and in trial populations. Should we still keep using the ALSFRS-R in clinical trials?#alsmndsympHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Great way to start the MNDA Symposium with the WFN satellite meeting about clinical trials, treatments for familial als, new biomarkers and outcome measures
#alsmndsymppic.twitter.com/eZPm2KjdUa
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Ruben van Eijk proslijedio/la je Tweet
Excellent meeting in Utrecht organised by
@LeonardvandBerg and colleagues to launch the@TRICALS_cureALS initiative, paving the way for more efficient and more effective#ALS#MND trials in Europe. Great to see so much industry interest!pic.twitter.com/4WowIsyeM3
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Ruben van Eijk proslijedio/la je Tweet
1ST for mankind this morning- sub 2hr marathon 1:59:40 amazing Kenyan
@EliudKipchogepic.twitter.com/dz1w0KJJam
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Great effort and very valuable to read the patient's opinion about trial participation, these kind of data can help significantly to design better clinical trials in the near future!https://twitter.com/bsw5020/status/1179934129716154373 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Ruben van Eijk proslijedio/la je Tweet
I am so thrilled to announce that we will be running a clinical trial for MND!
#collaborationiskey#RobHenderson@LeonardvandBerg@AmmarAlChalabi@Fred_Steyn@rpavaneijk#JPLoefflerhttps://twitter.com/AIBNatUQ/status/1173839016686493698 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Ruben van Eijk proslijedio/la je Tweet
the authoritative guide to clinical trials for ALS just arrived in the post. Thanks and congratulations
@rpavaneijkpic.twitter.com/vwskAptpDE
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Ruben van Eijk proslijedio/la je Tweet
Good illustration of progress in cancer control, albeit with some notable exceptions.pic.twitter.com/q8mOZ2j2OA
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The end of an era: PhD thesis approved and printed, defense is September 17th in Utrecht! I would like to thank all who contributed, especially
@LeonardvandBerg and@ReneEijkemans. Hope this thesis shortens the road towards a cure for#ALS#MNDpic.twitter.com/IjJQHmhMIW
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Ruben van Eijk proslijedio/la je Tweet
Clinical trials in
#ALS#MND could be made more efficient with some simple changes, such as extending follow-up for patients enrolled early. Our tool to help improve trial design is here: http://reactive.tricals.org and the paper describing our findings here:https://jnnp.bmj.com/content/early/2019/07/10/jnnp-2019-320998 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.